These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 15353489)
1. Elevations in troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non-ST-segment-elevation acute coronary syndromes. Bolognese L; Ducci K; Angioli P; Falsini G; Liistro F; Baldassarre S; Burali A Circulation; 2004 Sep; 110(12):1592-7. PubMed ID: 15353489 [TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. Bolognese L; Falsini G; Liistro F; Angioli P; Ducci K; Taddei T; Tarducci R; Cosmi F; Baldassarre S; Burali A J Am Coll Cardiol; 2006 Feb; 47(3):522-8. PubMed ID: 16458130 [TBL] [Abstract][Full Text] [Related]
3. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. Kastrati A; Mehilli J; Neumann FJ; Dotzer F; ten Berg J; Bollwein H; Graf I; Ibrahim M; Pache J; Seyfarth M; Schühlen H; Dirschinger J; Berger PB; Schömig A; JAMA; 2006 Apr; 295(13):1531-8. PubMed ID: 16533938 [TBL] [Abstract][Full Text] [Related]
4. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study. Leoncini M; Toso A; Maioli M; Bellandi F; Badia T; Politi A; De Servi S; Dabizzi RP Am Heart J; 2005 Sep; 150(3):401. PubMed ID: 16169315 [TBL] [Abstract][Full Text] [Related]
5. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30). Gibson CM; Kirtane AJ; Morrow DA; Palabrica TM; Murphy SA; Stone PH; Scirica BM; Jennings LK; Herrmann HC; Cohen DJ; McCabe CH; Braunwald E; Am Heart J; 2006 Oct; 152(4):756-61. PubMed ID: 16996854 [TBL] [Abstract][Full Text] [Related]
6. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Wong GC; Morrow DA; Murphy S; Kraimer N; Pai R; James D; Robertson DH; Demopoulos LA; DiBattiste P; Cannon CP; Gibson CM Circulation; 2002 Jul; 106(2):202-7. PubMed ID: 12105159 [TBL] [Abstract][Full Text] [Related]
7. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions. Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316 [TBL] [Abstract][Full Text] [Related]
8. Treatment modalities of non-ST-elevation acute coronary syndromes in the real world. Results of the prospective R.OS.A.I.-2 registry. Registro Osservazionale Angina Instabile Investigators Ital Heart J; 2003 Nov; 4(11):782-90. PubMed ID: 14699708 [TBL] [Abstract][Full Text] [Related]
9. Preservation of myocardial microcirculation during mechanical reperfusion for myocardial ischemia with either abciximab or eptifibatide. Stoupakis G; Orlando J; Kalia H; Skurnick J; Saric M; Arora R J Invasive Cardiol; 2003 Sep; 15(9):476-80. PubMed ID: 12947204 [TBL] [Abstract][Full Text] [Related]
10. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318 [TBL] [Abstract][Full Text] [Related]
11. Tissue characteristics of culprit lesion and myocardial tissue-level perfusion in non-ST-segment elevation acute coronary syndromes: The EARLY-MYO-ACS study. Yang G; Wang W; Sheng X; Yang F; Kong L; He J; Ding S; Shan P; Shang Y; Xiu J; Yang Y; Mintz GS; Pu J Int J Cardiol; 2019 Jul; 287():32-38. PubMed ID: 30772013 [TBL] [Abstract][Full Text] [Related]
12. Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors. Maioli M; Zeymer U; van 't Hof AW; Gibson CM; Dudek D; Bellandi F; Noc M; Secco GG; Zorman S; Gabriel HM; Emre A; Cutlip D; Rakowski T; Gyongyosi M; Huber K; De Luca G; J Invasive Cardiol; 2012 Jul; 24(7):324-7. PubMed ID: 22781470 [TBL] [Abstract][Full Text] [Related]
13. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial. Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442 [TBL] [Abstract][Full Text] [Related]
14. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958 [TBL] [Abstract][Full Text] [Related]
15. Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome. De Servi S; Mariani M; Vandoni P; Dellavalle A; Politi A; Poletti F; Bonizzoni E; Leoncinie M; J Cardiovasc Med (Hagerstown); 2006 Mar; 7(3):159-65. PubMed ID: 16645379 [TBL] [Abstract][Full Text] [Related]
16. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type]. Galli M; Maggioni AP; Vassanelli C; Tavazzi L Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377 [TBL] [Abstract][Full Text] [Related]
17. [Increase in troponin levels after coronary angioplasty (PTCA) in stable angina pectoris]. Varvarovský I; Brtko M; Branny M Vnitr Lek; 2004 Mar; 50(3):203-7. PubMed ID: 15125370 [TBL] [Abstract][Full Text] [Related]
18. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial. Gabriel HM; Oliveira JA; da Silva PC; da Costa JM; da Cunha JA Catheter Cardiovasc Interv; 2006 Aug; 68(2):218-24. PubMed ID: 16817177 [TBL] [Abstract][Full Text] [Related]